Photographer: Anne-Li Engström
Pipeline meetings are an important source of information for Amgros when we, through Horizon Scanning, forecast which medicines are likely to be marketed on the Danish market.
At the meetings, we talk about which medicines will be marketed in Denmark over the next two to three years.
Ahead of a pipeline meeting, we ask the supplier to provide specific and structured information about relevant medicines. This may include:
- Active substance and brand name
- Planned indication
- Medical value compared to current treatment
- Timeline for application, approval and launch
- Patient population likely to be relevant for the medicine in Denmark
- Possible budgetary implications
- Information on upcoming patent expiries
- Expected price
- Identification of structural barriers for new innovative treatments
Amgros is represented by relevant departments. From the regions, participants include members of drug committees, implementation units and clinical pharmacologists.
Amgros always treats information from pipeline meetings confidentially. However, we share knowledge and data with those attending the meetings and, when relevant, with the Danish Medicines Council.
Please note that Amgros, as well as other participants at the meeting, are subject to the Danish Access to Public Administration Files Act.
We prefer to hold pipeline meetings in person, but it is also possible to arrange hybrid meetings. Depending on the number of participants wishing to join online, we may decide to convert a hybrid meeting into a fully virtual meeting.
Our pipeline meetings generally last one hour.
Please note that the purpose of these meetings is to discuss medicines that may be marketed in Denmark within the next two to three years. We agree in advance on which medicines will be discussed.
If you would like to book a pipeline meeting, you are very welcome to contact us at medicin@amgros.dk.
Read more
Horizon Scanning
With Horizon Scanning, Amgros creates a comprehensive overview of new medicines and indication extensions expected to be marketed in Denmark within the next two to three years. This overview enables the Danish Medicines Council to plan its work well in advance. At the same time, it provides Amgros with a stronger basis for preparing upcoming price negotiations with suppliers and organising tendering procedures. We also prepare financial estimates that give the regions a solid foundation for planning their medicine budgets. These estimates take into account both new, often more expensive treatments and potential savings when lower-cost alternatives enter the market.
READ MOREHorizon Scanning overviews
Horizon Scanning prepares lists of new medicines, extensions of indication and other extensions undergoing evaluation by the EMA.
READ MORE
Find your way through EMA
Horizon Scanning draws, among other sources, on information from the European Medicines Agency (EMA). We continuously register and monitor pharmaceutical companies’ applications to the EMA. We communicate the collected information through the briefings and overviews that we publish on our website.
READ MORELatest news
If you would like to receive news from Amgros directly in your inbox, sign up for our newsletter. You can choose between general news or the latest news from Horizon Scanning.
SIGN UP